Multiple Sclerosis Market Analysis & Forecasts Report 2007-2022

The World Health Organization (WHO) estimates that over 2.5 million people globally suffer from Multiple Sclerosis (MS). With the present global population growing to an unprecedented height of 6.5 billion in 2005 and growth rate anticipated to reach 7.6 billion by 2020, the prevalence and onset of MS in children and particularly adults is expected to rise exponentially.

According to the National Multiple Sclerosis Society, an approximated 400,000 Americans have MS. In Europe over 500,000 are projected to have MS with large economic implications to healthcare providers. The clinical presentation of sufferers of the various forms of MS, over the past decade, have been treated with the following FDA approved disease modifying drugs (DMDs)-

> Avonex (interferon beta-1a; Biogen Idec)

> Betaseron (interferon beta-1b; Berlex, Inc./Schering)

> Copaxone (glatiramer acetate; Teva and Sanofi- Aventis)

> Novantrone (mitoxantrone; Serono International)

> Rebif (interferon beta-1a; Serono/Pfizer) and

> Tysabri (natalizumab; Biogen Idec and Elan Corp) re-entry into the market in July 2006

In 2006, the disease modifying drugs generated total global revenues of $5.4 billion, with a larger percentage of this revenue accounted for in the seven major markets (7MMs)- US, Japan, France, Germany, Italy, UK, and Spain. Visiongain believes that, as the larger Biopharmaceutical companies behind these products continue to advance on the product lifecycle of these disease modifying drugs, MS pharmaceutical treatments in these major markets are set to experience increased revenues. To find out exactly how big these increases will be, you should order this report today.

The disease modifying drugs on the MS market although effective are administered intravenously, intramuscularly or subcutaneously with much discomfort to MS patients. This has prompted a new wave of R&D heralded by top biopharmaceutical companies- Biogen Idec (BG-12), BioMS (MBP8298), Genzyme (Alemtuzumab), Merck Serono (Mylinax),Novartis (FTY720) ,Pipex (Trimesta), Sanofi-Aventis (Teriflunomide) and Teva (Laquinomod) into delivering oral MS therapeutics presently in late phase clinical studies to the markedly underserved MS market.

Visiongain believes the entry of a first oral MS product into the market will oscillate the markets’ dynamics, which have been long dominated by injectable products, and in doing so will acquire a significant market share. Furthermore the successful product will set a benchmark for a fray of other compounds to penetrate the oral therapeutics sector worth over $26 billion globally.

Visiongain’s Multiple Sclerosis Market Analysis & Forecasts Report, 2007-2022, delivers information on a vast array of compounds, in various phases of clinical trials, being investigated to improve on the clinical efficacy of present therapies and also bring relief to patients experiencing relapsing-remitting MS (RRMS), Primary progressive MS (PPMS), Secondary progressive MS (SPMS) often followed by (RRMS). This report presents strategies employed by top companies to increase their year-on-year fiscal consolidation of revenues through the delivery of more than one product into the market. The report also presents an in-depth analysis on why the UK MS market is lagging behind its EU counterparts in terms of MS disease modifying drugs annual turn-over, despite being one of the strongest markets in the EU.

With country-by-country focus on the markets of:

> US

> UK

> Germany

> Japan

> France

> Italy

> Spain

This report includes detailed five-year forecasts over the period 2007-2012, and NOW features 10 and 15 year forecasts to help you understand the medium-term prospects for these markets.

Why You Must Buy This Report:

This report features tables, graphs and charts, news, insights, the past and present developments in Market. This report will provide you with the complete understanding of the market indications for MS, the competition between companies into bringing the first oral MS product to revolutionized MS treatment, coupled with the domination of market share. When you buy this report, you will also get an understanding, through our overview, of how present changes in Governmental Pharmaceutical Policies will impact on the market strength of MS products in the 7MM. The Multiple Sclerosis Market Analysis & Forecasts 2007-2022 report is a must buy, because it presents in-depth and unbiased financial analysis for the near-term, medium-term and the long-term, market dynamics. When you buy the Visiongain 2007 MS report, you will be buying current and vital information on the growing prevalence of Paediatric MS and the value it adds to the global MS market.

Key questions that this report answers are:

> How companies intend to sustain long term year-on-year MS revenues growth?

> What strategic advancement on product lifecycle will boost revenues in the long- term?

> What influence US Medicare Part D will have on the potential growth of US DMDs market?

> Which companies are at the forefront of oral MS R&D?

> Which oral compounds are in late phase studies?

> Which company’s oral product is imminent to reach the market?

> What decisions influenced UK NICE approval of Tysabri?

> Why Tysabri will rejuvenate the UK MS market?

> Will the DMDs in the 10-year (2002-2012) UK NICE “Risk Sharing Scheme” be cost-effective after 2012?

> What is Paediatic MS and which treatments are preferred?

Unique benefits to you when you order this report:

- Primary research throughout. You will not find this information anywhere else

- Report stored in your reading room for ever

- Full searchable report when you buy the company or corporate editions

- Copies can be printed off for offline reading

- Packed with charts, analysis, figures, graphs and tables

Septmber 2007 PDF No pages: 170
Table of Contents
Sample Pages

Price
Single User Licence $2995.00
Department Licence 5 Users $5995.00
Company-wide Intranet Licence $9995.00